Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL28769040 | 0.97 | PKM (0.39) | PKMCTRB1DGAT1ALDH1A1KCNN4 | |
| SCHEMBL21375478 | 0.84 | CTRB1 (0.39) | PKMCTRB1DGAT1ALDH1A1KCNN4 | |
| SCHEMBL11216608 | 0.84 | CTRB1 (0.39) | PKMCTRB1DGAT1ALDH1A1KCNN4 | |
| SCHEMBL10601712 | 0.82 | CTRB1 (0.38) | PKMCTRB1DGAT1ALDH1A1KCNN4 | |
| SCHEMBL17067292 | 0.81 | CTRB1 (0.40) | CTRB1DGAT1ALDH1A1KCNN4GAA | |
| SCHEMBL503350 | 0.81 | PKM (0.37) | PKM | |
| SCHEMBL20817069 | 0.80 | POLB (0.39) | CTRB1ALDH1A1GAA | |
| SCHEMBL10496264 | 0.79 | PKM (0.35) | PKM | |
| SCHEMBL765780 | 0.79 | DGAT1 (0.41) | CTRB1DGAT1ALDH1A1KCNN4 | |
| SCHEMBL19915241 | 0.79 | PKM (0.35) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102880-A1 | FULL-TEMPERATURE-RANGE POLYMER-BASED SOLID ELECTROLYTE, SOLID-STATE BATTERY AND PREPARATION METHOD | 固态离子能源科技(武汉)有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-119490607-A | Full-temperature-range polymer-based solid electrolyte, solid battery and preparation method | 固态离子能源科技(武汉)有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-118040044-A | Electrolyte additive, electrolyte and lithium ion battery | 南昌大学 | 2024-05-14 | — | — | CN | claimed |
| CN-117613372-A | Secondary battery and electricity utilization device | 欣旺达动力科技股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-116253861-B | Spraying airtight plugging polyurethane foam and preparation method thereof | 北京北开中电电气设备有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-116315071-A | Wide-temperature solid electrolyte | 上海交通大学绍兴新能源与分子工程研究院 | 2023-06-23 | — | — | CN | claimed |
| CN-116253861-A | Spraying airtight plugging polyurethane foam and preparation method thereof | 北京北开中电电气设备有限公司 | 2023-06-13 | — | — | CN | claimed |
| EP-2978756-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Pharma AG (DE) | 2019-03-27 | — | — | EP | claimed |
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | claimed |
| EP-3197891-B1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | Bayer Pharma AG (DE) | 2018-11-21 | — | — | EP | claimed |
| EP-3024822-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE AS FACTOR XIA AND PLASMA KALLIKREIN INHIBITORS | Bayer Pharma AG (DE) | 2017-05-03 | — | — | EP | claimed |
| US-20170035739-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | claimed |
| US-9475809-B2 | Substituted oxopyridine derivatives and use thereof as factor xia/plasma | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-25 | — | — | US | claimed |
| US-9434690-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-06 | — | — | US | claimed |
| US-20160152613-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-02 | — | — | US | claimed |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | claimed |
| EP-2978756-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | claimed |
| WO-2014154794-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | WO | claimed |
| US-20140227611-A1 | Non-Aqueous Secondary Battery | NEC CORPORATION (JP) | 2014-08-14 | — | — | US | claimed |
| US-5336801-A | Reacting a cyanide salt, water and tetrafluoroethylene in the presence of an acyclic alcohol | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152613-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA | F11, F2, F10 | PKM 1449/4885CTRB1 1784/4885DGAT1 4099/4885 |
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | F13B, TFPI, TFPI2 | PKM 1482/4885CTRB1 127/4885DGAT1 4575/4885 |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | OGFOD1, PNPO, VASP | PKM 653/4885CTRB1 3327/4885DGAT1 2736/4885 |
| US-20170035739-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA | F11, F2, F10 | PKM 1449/4885CTRB1 1784/4885DGAT1 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.